With respect to Investment liberalisation – National treatment:

In **LV**: In order to commence independent practice in a pharmacy, a foreign pharmacist or pharmacist's assistant, educated in a state which is not a Member State of the European Union or a Member State of the EEA, must work for at least one year in a pharmacy under the supervision of a pharmacist.

With respect to Investment liberalisation – Market access, National treatment and Cross-border trade in services – Market access, National treatment:

In **BG** and **EE**: The retail of pharmaceuticals and specific medical goods to the public may only be carried out through a pharmacy.

In **BG**: The mail order of pharmaceuticals is prohibited. Permanent residency is required for pharmacists. Managers of pharmacies must be qualified pharmacists and may only manage one pharmacy in which they themselves work. A quota exists for the number of pharmacies which may be owned per person.

In **EE**: Mail order sale of medicinal products as well as delivery by post or express service of medicinal products ordered through the Internet is prohibited. Establishment authorisation is subject to an economic needs test. Main criteria: density conditions in the area.

With respect to Investment liberalisation - Market access and Cross-border trade in services - Market access:

In **SK**: Residency is required in order to obtain a licence as a pharmacist or to open a pharmacy for the retail of pharmaceuticals and certain medical goods to the public.

With respect to Investment liberalisation - Market access

In **DK**: Only natural persons, who have been granted a pharmacist-licence from the Danish Health and Medicines Authority, are permitted to provide retail services of pharmaceuticals and specific medical goods to the public.

Measures:

AT: Apothekengesetz (Pharmacy Law), RGBl. Nr. 5/1907 as amended, §§ 3, 4, 12; Arzneimittelgesetz (Medication Act), BGBl. Nr. 185/1983 as amended, §§ 57, 59, 59a; and Medizinproduktegesetz (Medical Products Law), BGBl. Nr. 657/1996 as amended, § 99.

BG: Law on Medicinal Products in Human Medicine, arts. 146, 161, 195, 222, 228.

CY: Pharmaceutical and Poisons Law (Chapter 254).